Investment
Features
FeesSafety
Academy
More
Pluang+

Empery Digital sold 1,635 BTC for $102.2M, cutting unrestricted holdings 76% to 325 BTC amid debt repayment and new investments.

Market News
10 Aug 2026
Crypto news
View Source
Bearish
pluang ai news

Empery Digital sold 1,635 Bitcoin for $102.2 million between July 1 and August 6, 2026, reducing its total holdings to 1,279 BTC with only 325 BTC unrestricted after pledging 954 BTC against $35 million debt. This marks a 76% drop in unrestricted Bitcoin since June 30, as the company focuses on debt repayment, share buybacks, and new investments including a potential AI data center property acquisition. Empery’s strategy has shifted from expanding Bitcoin holdings to managing leverage and capital allocation, with further Bitcoin sales possible depending on upcoming property deal outcomes. The company had $3.6 million in cash and a working capital deficit as of June 30, highlighting ongoing financial adjustments.

More News

Bitcoin reserves rise on major exchanges as U.S. trading volume on Binance surges, signaling higher market liquidity.

Bitcoin reserves rise on major exchanges as U.S. trading volume on Binance surges, signaling higher market liquidity.

Bitcoin balances on major exchanges increased notably, with a net inflow of over 1,100 BTC in 24 hours and more than 6,400 BTC over a month, reflecting growing sell-side readiness and trading activity. Binance saw a sharp rise in U.S. trading hours v...

Market News
Neutral
4 hours ago
Sobi partners with Innate Pharma to advance lacutamab Phase 3 trial for T-cell lymphoma treatment

Sobi partners with Innate Pharma to advance lacutamab Phase 3 trial for T-cell lymphoma treatment

Swedish Orphan Biovitrum (Sobi) and Innate Pharma have formed a strategic partnership to initiate the TELLOMAK-3 Phase 3 trial for lacutamab, targeting cutaneous T-cell lymphoma (CTCL), including Sézary syndrome. This trial is a key step toward accel...

Company Fundamentals
Bullish
4 hours ago
ImmuPharma appoints Kymos as bioanalytical partner for diabetes drug Kapiglucagon development

ImmuPharma appoints Kymos as bioanalytical partner for diabetes drug Kapiglucagon development

ImmuPharma has appointed Kymos Group as the bioanalytical partner for its diabetes drug candidate Kapiglucagon, completing its outsourced development team. Kymos will develop and validate methods to measure the drug in biological samples and analyze ...

Market News
Bullish
4 hours ago
Bitcoin demand rebounds but needs stronger spot buying to sustain recovery above $67K resistance.

Bitcoin demand rebounds but needs stronger spot buying to sustain recovery above $67K resistance.

Bitcoin's 30-day demand has turned positive near 25,000 BTC after a sharp drop, signaling returning capital mainly driven by derivatives. However, for a sustainable recovery, stronger spot market participation is needed to absorb overhead supply and ...

Market News
Bullish
4 hours ago
ASM International starts €150M share buyback program through December 2026

ASM International starts €150M share buyback program through December 2026

ASM International N.V. has launched a share buyback program worth up to €150 million, starting August 10, 2026, and continuing until the total purchase reaches €150 million or by December 2026. The buyback is authorized by the company's management an...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App